Gedeon Richter Licenses Women's Health Pipeline to Lilly
Richter grants Eli Lilly exclusive worldwide rights to jointly developed women's health and cardiometabolic medicines, plus an option on an oral estrogen therapy.
Updated on Nov. 13, 2026 in Women’s Health
Live Poll
Do you trust new menopause treatments to be worth what they cost you?
Hungarian drugmaker Gedeon Richter has entered a licensing agreement with Eli Lilly and Company covering jointly developed medicines for women's health conditions and cardiometabolic diseases. Lilly will also acquire 381,354 Richter ordinary shares held in treasury for approximately USD 15 million, with an upfront cash payment due at closing.
Why it matters
The deal extends Richter's estrogen-based pipeline into a large global partner's commercial reach, with milestone payments and tiered royalties tied to future sales. It also gives Lilly a foothold in menopause care, an area with significant unmet medical need.
The transaction includes 381,354 Richter ordinary shares acquired for approximately USD 15 million, and E4 is authorized in more than 50 countries as the estrogen component of a combined oral contraceptive. Financial terms for the upfront cash payment, milestones and royalties were not disclosed, and the U.S. regulatory outcome for the estrogen monotherapy remains pending.
The players
Gedeon Richter
Gedeon Richter is a Hungarian pharmaceutical company with a long-established women's health portfolio and a focus on hormone-based therapies.
Eli Lilly and Company
Eli Lilly and Company is a large U.S. pharmaceutical manufacturer known for its diabetes, obesity and cardiometabolic medicines.
The details
Under the agreement, Richter grants Lilly exclusive worldwide rights to develop, manufacture and commercialize the jointly developed medicines and supplies the active ingredient Estetrol (E4) under a separate supply agreement. Richter is eligible for regulatory and commercial milestone payments and tiered royalties on net sales, and Lilly holds an option to co-commercialize its oral E4-based estrogen monotherapy FYLREVY® in the United States. FYLREVY® is already authorized in the European Economic Area for hormone replacement therapy in postmenopausal women and is sold in Hungary, the Czech Republic, Slovakia, Finland and Sweden.
Timeline
November 13, 2026: Licensing agreement and share transaction announced.
Upon closing: Lilly makes its upfront cash payment and acquires the treasury shares.
Health Landscape
The deal extends Estetrol (E4), already authorized in more than 50 countries as the estrogen in combined oral contraceptives, into hormone replacement therapy and cardiometabolic care. It reflects a pattern of mid-sized European drugmakers partnering with large U.S. firms to reach global markets for women's health products.
For women in the European Economic Area and five Nordic and Central European markets, FYLREVY® is already available as a hormone replacement therapy option. U.S. patients will have to wait for FDA review of the estrogen monotherapy before it can be prescribed for menopause symptoms.
The takeaway
Menopause treatment options may broaden as partnerships bring newer estrogen therapies to more countries, but availability depends on local regulatory approval. Patients should discuss hormone therapy options with a clinician based on their individual health profile.
Further reading
Explore more coverage in our Women's Health section.
Source note: This article includes information reported by Hungary Today.
Live Poll
Do you trust new menopause treatments to be worth what they cost you?
